10x Genomics
Open
$21.93
Prev. Close
$21.93
High
$21.95
Low
$21.85
Market Snapshot
$2.56B
-58.7
-1.53
$610.79M
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
10x Genomics' Atera platform launch helped boost its share price by 28.58% year-to-date, despite facing challenges with long-term returns.
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Recently from Cashu
10x Genomics Faces Challenges Amid NIH Funding Cuts Impacting Life Science Tools Sector
Impact of NIH Funding Cuts on Life Science Tools Sector The recent decision by the Trump administration to impose a significant cap on indirect costs funded by the National Institutes of Health (NIH)…
10x Genomics Reports Mixed Q4 Results with Growth in Services Amid Instrument Declines
10x Genomics Reports Mixed Financial Results Amidst Growth in Services Sector 10x Genomics, Inc., a leader in single-cell and spatial biology, presents its preliminary financial results for the fourth…
10x Genomics Reports Mixed Financials with Resilient Growth in Consumables and Services
10x Genomics Reports Resilient Growth in Services and Consumables Amid Mixed Financial Results 10x Genomics, Inc. continues to solidify its position as a leader in single cell and spatial biology, ref…